ViaCyte's potential diabetes 'cure' gets another $6m to move into human trials
This article was originally published in Scrip
Executive Summary
With another $6 million to fund ViaCyte's stem cell-based diabetes product, which the San Diego-based company has said could reduce or eliminate the need for pharmaceutical insulin, the Juvenile Diabetes Research Foundation (JDRF) has contributed $7 million and the California Institute for Regenerative Medicine (CIRM) has financed nearly $40 million in preclinical work for the VC-01 therapeutic and device combination product.